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Abstract
Background: Thrombosis after liver transplantation is a leading cause of graft loss, 
morbidity, and mortality. Several known recipient- and surgery-related characteris-
tics have been associated with increased risk of thrombosis after transplantation. 
Potential donor-related risk factors, however, remain largely undefined.
Objectives: We aimed to identify risk factors for early post-transplantation throm-
bosis (<90 days) and to determine the impact of early postoperative thrombosis on 
long-term graft and patient survival.
Patients/Methods: A post hoc analysis was performed of an observational cohort study 
including all primary, adult liver transplantations performed between 1993 and 2018. 
Donor-, recipient-, and surgery-related characteristics were collected. Competing risk 
model analyses and multivariable regression analyses were performed to identify risk 
factors for developing early post-transplant thrombosis and graft failure.
Results: From a total of 748 adult liver transplantations, 58 recipients (7.8%) devel-
oped a thrombosis after a median of 7 days. Post-transplantation thrombotic events 
included 25 hepatic artery thromboses, 13 portal vein thromboses, and 22 other 
thrombotic complications. Donor history of smoking was independently associated 
with early postoperative thrombosis (odds ratio [OR] 2.42; 95% confidence interval 
[CI], 1.29-4.52). Development of early post-transplant thrombosis was independently 
associated with patient mortality (hazard ratio [HR] 3.61; 95% CI 1.54-8.46) and graft 
failure (HR 5.80, 95% CI 3.26-10.33), respectively.
Conclusion: Donor history of smoking conveys a more than two-fold increased risk of 
thrombosis after liver transplantation, independent of other factors. Post-transplant 
thrombosis was independently associated with decreased patient and graft survival.
K E Y W O R D S
graft survival, hepatic artery thrombosis, liver transplantation, portal vein thrombosis, risk factors
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1  | INTRODUC TION
Postoperative thrombosis is a potentially life-threatening com-
plication for orthotopic liver transplantation (OLT) recipients, 
which impairs graft survival and contributes significantly to ad-
verse outcomes.1,2 Studies in both pediatric and adult cohorts es-
timate an incidence of thrombotic events in up to 26% of cases. 
The most common types of thrombosis after liver transplantation 
are hepatic artery thrombosis (HAT) and portal vein thrombosis 
(PVT), which are reported at rates from 2% to 9% and 3% to 15%, 
respectively.3-6
Previous studies have suggested that, in addition to technical 
difficulties during surgery, donor/recipient size and immunological 
mismatches, rejection, re-transplantations, and specific donor char-
acteristics such as age or weight (summarized in Table S1 in sup-
porting information) can lead to an increased risk of early HAT or 
PVT.7-9 The exact mechanism is unknown; however, dysregulated 
hemostasis and liver disease-related hypercoagulation have been 
proposed to play a substantial role.10,11 Patients with a liver dis-
ease can present with hemostasis-related bleeding episodes, but 
may also be at risk for developing thromboembolic complications. 
The hemostatic capacity of patients with liver disease appears to 
be more easily disturbed compared to healthy individuals, which 
leads to a “rebalanced hemostasis” in the early phase of a post liver 
transplant patient.12
Therefore, the aim of this study was to identify which of 
these donor, recipient, and surgical characteristics are risk fac-
tors for early postoperative thrombosis in adult OLT recipients, 
and additionally to evaluate the effect of early postoperative 
thrombosis on short- and long-term graft survival and patient 
mortality.
2  | METHODS
2.1 | Study design and patients
A post hoc analysis of an observational cohort study of adult pa-
tients, who underwent a primary OLT at the University Medical 
Center Groningen, the Netherlands, between January 1993 and 
February 2018 was performed. Adult (age ≥ 18 years) OLT recipi-
ents with clinical recording and follow-up data were included in the 
study cohort. Only primary liver transplantations were included in 
our study (Figure 1). Heparin was not routinely administered peri-
operatively. All patients in our study received daily subcutane-
ous injections of Fraxiparine dosed at 2850 IU, starting at 6 hours 
post-transplantation. We collected all necessary data from exist-
ing databases and patient records, with a follow-up period until 
May 2018. Patient information before and during transplantation, 
3 months after transplantation, and until end of follow-up period 
Essentials
• Little is known about donor-related risk factors for de-
veloping post-transplant thrombosis.
•  An observational study including primary adult liver 
transplantations between 1993-2018.
• A significantly higher incidence of graft loss was found 
in patients with thrombosis.
• Donor history of smoking was associated with an in-
creased risk of post-transplant thrombosis.
F I G U R E  1   Consort diagram of patients 
included in the study. Flow diagram 
showing inclusion/exclusion and follow-up 
period
1314 Liver transplantation procedures
from January 1993 to February 2018
Exclude re-transplantation procedures
n = 228
Exclude recipients under 18 years
n = 328
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was collected. In addition, phenotypic and biochemical data of the 
donors was collected. The observational cohort study was regis-
tered in the Netherlands Trial Register (www.trial regis ter.nl; Trial 
NL6334) and was conducted within the TransplantLines cohort 
(TransplantLines; METc 2014/77). STROBE (Strengthening the 
Reporting of Observational Studies in Epidemiology) guidelines for 
reporting observational studies were adhered to.13
2.2 | Definitions and variables
Early postoperative thrombosis was defined as any thrombotic 
event within the first 90 days after primary OLT. A thrombotic 
event was defined as a thrombus which was clinically suspected 
after OLT and later confirmed intraoperatively or with clini-
cal imaging (ultrasound/angiography/computed tomography). 
Thrombotic events included HAT, PVT, and other postoperative 
vascular complications like pulmonary embolism, deep vein throm-
bosis, and venous outflow tract obstruction. HAT was defined as 
radiologically or surgically proven thrombosis of the hepatic ar-
tery. PVT was defined as radiologically or surgically proven throm-
bosis of the portal vein.
Patient survival was defined as time from OLT to death or end of 
follow-up (censored at 10 years after baseline or on May 1, 2018). 
Graft survival was defined as time between date of OLT and date of 
graft failure, death, or end of follow-up.
2.3 | Statistical analysis
Continuous data were presented as medians with interquartile ranges 
(IQR), and categorical data were presented as number (percentages). 
Mann-Whitney U and Pearson chi-square tests were used to test for 
differences in continuous and categorical variables, respectively. We 
compared all relevant donor, recipient, and surgical variables between 
the HAT, PVT, and all thrombotic events group versus non-thrombotic 
OLT recipients. Variables with a P-value < .1 in the univariable analysis, 
with valid data of more than 80%, were included in the multivariable 
analysis and were regarded as possible confounders and included in 
the risk models. Multivariable logistic regression analysis using a for-
ward stepwise selection method was used to examine the independ-
ent association between candidate factors and the occurrence of 
thrombosis. In model 1, we performed a crude regression analysis. In 
model 2, we cumulatively adjusted for significant recipient variables 
in the univariable analysis (P < .1). In model 3, we cumulatively ad-
justed for the significant donor variables. In model 4, we cumulatively 
adjusted for the significant surgical variables. In model 5, we cumula-
tively adjusted for the other significant variables. Finally, in model 6 we 
cumulatively adjusted for potential confounders that were reported 
in previous studies. Results were presented as odds ratios (ORs) with 
corresponding 95% confidence intervals (CIs).
A competing risk survival analysis was performed within the 
dataset to evaluate patient and graft survival, which is an alternative 
method for analyzing competing risks of graft survival and patient 
death. The outcomes “patient death” and “graft failure” were in-
cluded in the competing risk model. Cox regression analysis was 
used to compare graft survival and patient mortality in thrombo-
sis and non-thrombosis groups. Cox proportional hazard models 
were constructed to adjust for potential confounders. All reported 
P-values are two-tailed and considered statistically significant if 
P < .05. Statistical analyses were conducted with the use of SPSS 




We analyzed 748 adult patients who underwent a primary OLT for a 
variety of indications. Donor, recipient, and surgical characteristics 
are shown in Table 1. After a median (IQR) of 74-22 days after OLT, 58 
of 748 (7.8%) patients developed postoperative thrombosis. HAT oc-
curred in 25/58 patients (time to event, 6 [2-20] days), PVT in 13/58 
patients (time to event, 6 [4-15] days), and 22/58 (time to event, 14 
[6-26] days) patients experienced other postoperative thrombotic 
complications. Total hospital- and intensive care unit (ICU) stay were 
significantly longer in the group of patients with any postoperative 
thrombotic event. Furthermore, the year of OLT was not signifi-
cantly different between thrombosis and non-thrombosis groups.
3.2 | Risk factors for post-transplant thrombotic 
complications
We compared all relevant donor, recipient, and surgical variables 
between the HAT, PVT, and all thrombotic events group versus non-
thrombotic OLT recipients. To obtain sufficient statistical power, we 
combined transplantation- and liver-specific thrombotic events (HAT 
and PVT). Parameters with a P-value < .1 in the univariable analy-
ses were used for further multivariable regression analyses. Thus, 
cytomegalovirus (CMV) positive donor status (D+), CMV donor/re-
cipient mismatch status (D+/R−), and donor history of smoking were 
included in the multivariable analysis for all postoperative thrombo-
ses. Recipient age, donor body mass index (BMI), donor history of 
smoking, partial graft and warm ischemia time (WIT) were included 
in the multivariable analysis for HAT and PVT. D+/R− CMV status 
and donor history of smoking were included in the multivariable 
analysis for other thrombotic events.
Univariable and multivariable regression analyses were per-
formed for the HAT/PVT group, the other thrombosis group, and the 
combined group of postoperative thrombotic events. Odds ratios for 
the tested variables are summarized in Table 2 and Figure 2. The 
univariable analysis shows an association between donor history of 
smoking and the development of any thrombotic event (OR, 2.42; 
95% CI, 1.29-4.52). In subgroup analyses, donor history of smoking 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































6  |     LI et aL.
remained associated with liver transplant specific (ie, HAT and PVT) 
thrombosis (OR, 2.30; 95% CI, 1.03-5.14) as well as with other 
thrombotic events (OR, 2.59; 95% CI, 0.99-6.77). The variables with 
a P-value < .1 were selected for further multivariable analysis.
In the multivariable analysis (Figure 2, Table S2 in supporting in-
formation), donor history of smoking was identified as an indepen-
dent predictor for developing any thrombotic event (OR 2.34; 95% 
CI, 1.23-4.45), as well as for developing HAT or PVT (OR 2.29; 95% 
CI, 1.02-5.13).
3.3 | Donor smoking as a risk factor for post-
transplant thrombosis
To identify donor smoking as an independent risk factor for early 
postoperative thrombosis, we adjusted for potential confounders 
identified in previous literature (Table S1) and variables from the uni-
variable regression analysis (Table 2). We found that donor history of 
smoking significantly increased the risk of all-cause thrombosis more 
than two-fold (Table 3, model 1: OR, 2.42; 95% CI, 1.29-4.52), when 
compared to non-smoking donors.
After adjusting for recipient-, donor-, and surgical-related factors 
and for previously reported confounders, donor history of smoking 
remained independently associated with postoperative thrombosis 
(Table 3, models 2-6).
The incidence of post-transplant thrombosis in recipients who 
received a liver from a donor without a history of smoking was 4.9%. 
In patients who received a liver from a donor with a history of smok-
ing, the incidence of thrombosis increased to 11.0%.
3.4 | Patient and graft survival
Postoperative thrombosis had a substantial effect on graft and pa-
tient survival. Of all patients who developed postoperative throm-
bosis, a total of 62.1% experienced graft failure after a median 
follow-up period of 14 years, compared to 43.2% of people without 
postoperative thrombosis (P = .005). Causes for patient mortality in-
clude infection (19.4%), any thrombotic event (3.9%), rejection (1.6%), 
primary non-function (PNF) (1.6%), and trauma (0.3%). Figure 3 
shows cumulative incidence functions for the progression to graft 
failure and patient death in HAT, PVT, total postoperative thrombo-
sis, and patients without thrombosis groups. Competing risk analysis 
within the categories of postoperative thrombosis showed that both 
HAT and PVT had a significant effect on early graft survival, and that 
especially patients with HAT were more likely to experience graft 
failure in the first 90 days (log-rank, P < .001; Figure 3A). In addition, 
development of PVT was associated with increased mortality within 
the first 90 days post-transplantation (log-rank, P = .026; Figure 3A). 
Ten-year competing risk analysis was performed using data from re-
cipients who had not experienced graft failure in the first 90 days. 
The analysis showed no significant difference in long-term patient 
and graft survival between all groups of thrombosis and without 
thrombosis for those who survived the first 90 days after transplan-
tation (log-rank, P = .35 and P = .32; Figure 3B).
In the Cox regression analysis, development of early post-trans-
plant thrombosis was significantly associated with patient mortality 
and graft failure with a hazard ratio [HR] of 3.61 (95% CI, 1.54-8.46) 
and 5.80 (95% CI, 3.26-10.33), respectively, when adjusted for po-
tential confounders including age, D+/R- CMV status, donor history 
of smoking, donor BMI, graft type, WIT, and ICU and hospitalization 
time.
4  | DISCUSSION
This study aimed to identify risk factors for thrombosis after OLT. 
Donor, recipient, and surgical parameters were collected and com-
pared between groups of patients with or without postoperative 
thrombotic complications. We have newly identified donor history 
of smoking as an independent risk factor for developing thrombo-
sis after OLT. In addition, we show that postoperative thrombotic 
complications mainly affect graft survival in the early postop-
erative phase (first 90 days), rather than long-term graft survival 
(Figure 3).
In this study, we confirmed previously reported risk factors, 
and identified new risk factors for early postoperative thrombotic 
complications. We initially analyzed HAT and PVT separately as 
transplantation-specific thrombotic complications. As Table 2 
shows, recipient age, donor BMI, donor history of smoking, and 
partial graft all were identified as potential risk factors for devel-
oping HAT/PVT. In our multivariable analysis, we have identified 
donor history of smoking as a new risk factor for developing any 
thrombotic event. Donor history of smoking was also confirmed 
as a risk factor for developing liver-specific thrombosis, HAT, and 
PVT. In addition, of the previously reported risk factors for post 
OLT thrombosis, lower recipient age and low donor BMI were con-
firmed for HAT and PVT in the univariable analysis.14 This infor-
mation is important when considering, for example, a liver graft 
from a donor with a low BMI and a history of smoking for a young 
recipient because of the increased risk of developing early postop-
erative thrombosis (Figure 2).
OLT candidates are strongly advised to quit smoking to decrease 
the risk of developing post-transplant thrombotic complications, as 
previous studies have identified a history of smoking in the recipient 
as an important risk factor.15 The effect of donor history of smoking 
has been found to increase patient mortality after HAT.16,17 It is un-
known how donor history of smoking causes thrombosis in the re-
cipient. However, previous studies have reported pathways in which 
cigarette smoking causes endothelial damage, which could even-
tually lead to thrombosis. These studies have shown that cigarette 
smoke has a cytotoxic effect on endothelial cells, both in vitro and 
ex vivo.18 In vitro studies with human umbilical vein endothelial cells 
and a variety of human and mammalian cell types have shown an in-
crease in the rate of cell death after exposure to cigarette smoke.19,20 
Heavy smokers also experienced impaired endothelium-dependent, 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































8  |     LI et aL.
nitric oxide (NO) flow-mediated vasodilatation.21 Additionally, 
Michaud et al reported that cigarette smoke exposure impairs vas-
cular endothelial growth factor (VEGF)-induced endothelial cell mi-
gration and tube formation. This increases the generation of reactive 
oxygen species (ROS), decreases expression of surface integrins, and 
blocks the Akt/eNOS/NO pathway.22 Our study has identified that 
a history of smoking in the donor was associated with increased risk 
of early postoperative thrombosis. In our patient cohort, donor cig-
arette smoking may be responsible for morphological and functional 
damage to the endothelium of the liver graft, which then may lead 
to thrombosis in the recipient. However, future research to confirm 
this pathway is needed.
An association between recipient CMV positive status and early 
postoperative thrombosis has already been shown in recent stud-
ies.23 Our study confirmed the use of seropositive CMV grafts as a 
potential risk factor for developing early postoperative thrombosis. 
However, there is limited recent data on the effect of seropositive 
CMV grafts on developing thrombotic complications, with the latest 
F I G U R E  2   Multivariable analyses of risk factors in thrombotic subgroups. BMI, body mass index; CMV, cytomegalovirus; HAT, hepatic 
artery thrombosis; PVT, portal vein thrombosis. Note: Odds ratio represents the odds of thrombotic events with a risk factor compared to 
the odds of thrombotic events occurring in the absence of this risk
Factors associated with all thrombotic events ( n = 58)
Odd Ratio (95%CI)
2.34 (1.23 ... 4.45)
1.45 (0.66 ... 3.19)
1.58 (0.78 ... 3.21)
2.29 (1.02 ... 5.15)
0.98 (0.95 ... 1.01)
0.98 (0.84 ... 1.07)
3.01 (0.60 ... 15.1)
1.02 (0.99 ... 1.04)
2.40 (0.89 ... 6.46)
2.34 (0.86 ... 6.36)
The estimates
0.5 1 2 3 4 5 61.5 2.5 3.5 4.5 5.5 6.5
Factors associated with HAT and PVT (n = 36)
Factors associated with other thrombosis (n = 22)
Donor history of smoking
Donor history of smoking








TA B L E  3   Association of donor smokers with postoperative thrombosis of liver transplant
No 
thrombosis
Overall postoperative thrombotic 
Group HAT + PVT Group Other thrombosis Group
Ref. OR (95% CI) P value OR (95% CI) P value OR (95% CI)
P 
value
No. of events 690 58 36 22
Model 1 1.00 2.42 (1.29-4.52) .006 2.30 (1.03-5.14) .042 2.59 (0.99-6.77) .052
Model 2 1.00 2.43 (1.30-4.54) .006 2.33 (1.04-5.20) .040 2.60 (0.99-6.79) .052
Model 3 1.00 2.34 (1.23-4.44) .010 2.23 (0.99-5.02) .054 2.55 (0.94-6.91) .066
Model 4 1.00 2.34 (1.25-4.41) .008 2.27 (1.01-5.09) .047 2.50 (0.94-6.61) .065
Model 5 1.00 2.43 (1.26-4.67) .008 2.44 (1.05-5.69) .039 2.45 (0.92-6.53) .073
Model 6* 1.00 4.48 (1.64-12.25) .003 3.57 (1.06-11.97) .040 6.70 (1.17-38.47) .033
Note: Model 1: Donor history of smoking
Model 2: model 1 + adjustment for recipient age.
Model 3: model 1 + adjustment for CMV D+/R- status, donor BMI and donor CMV + status.
Model 4: model 1 + adjustment for WIT and partial graft type.
Model 5: model 1 + adjustment for hospitalization and ICU days.
Model 6: model 1 + adjustment for potential confounders which were reported in previous studies.
Abbreviations: BMI, body mass index; CI, confidence interval; CIT, cold ischemia time; CMV, cytomegalovirus; HAT, hepatic artery thrombosis; ICU, 
intensive care unit; MELD, model for end-stage liver disease; OR, odds ratio; PVT, portal vein thrombosis; WIT, warm ischemia time.
*Adjusted confounders: recipient gender, recipient body weight, recipient BMI, recipient transplant indication, Child-Pugh score, MELD score, donor 
age, Roux-en-Y biliary-reconstruction, CIT, and blood loss. 
     |  9LI et aL.
findings dating back to 2006.24,25 Our results suggest an approxi-
mately 50% increase in the odds of any post-transplant thrombosis 
in patients with CMV D+ status or CMV D+/R− mismatch status. 
Nonetheless, odds ranging from a 34% decrease, a negative asso-
ciation, to a more than three-fold increase, a substantial positive 
association, is also reasonably compatible with our data, given our 
F I G U R E  3   Cumulative incidence curves demonstrating the association between postoperative thrombosis groups and progression to 
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assumptions. We hypothesize that this could, at least, partially be 
explained by CMV-mediated activation of endothelial cells, thereby 
interfering with donor hemostasis. The activated endothelial cells 
may subsequently promote liver-specific thrombosis in the recipient 
after OLT.26
The main limitation of this study is that because some variables 
had to be excluded from further analyses because of a relatively 
high number of missing values, it is possible that some important 
risk factors were missed. For example, major bleeding and blood 
product transfusions during transplantation might have an impact 
on thrombotic outcomes; however, they were not used in our analy-
ses due a high number of missing values. Further research is needed 
to explore this association. Because in our data set the thrombotic 
events HAT and PVT occurred relatively infrequently (3.3% and 
1.7%, respectively), we have combined them as a composite end-
point to gain statistical power. Although we acknowledge that HAT 
and PVT may have a different etiology when considering surgical 
and recipient risk factors, they are all specific to liver transplanta-
tion, and donor risk factors will likely contribute to all thrombotic 
events.
We included all OLTs performed during the last 25 years. As 
transplant care, including anesthesiology, surgery, intensive care, 
and post-transplant treatment, including immunosuppression, have 
substantially improved over time, we have investigated if the year of 
transplantation may confound our results. As mentioned before, we 
found no significant difference between year effect, indicating that 
the date of transplantation is unlikely to be a confounder. A strength 
of this study is the thorough investigation of the role of potential 
thrombosis risk factors, not only those reported previously. This 
has made it possible to identify new risk factors for postoperative 
thrombotic complications.
In conclusion, this study has identified donor history of smoking 
as an independent risk factor for developing thrombosis after OLT 
and has strengthened findings of previous studies. This study has also 
shown that the incidence of thrombosis leads to an increased inci-
dence of graft failure within the first 90 days after transplantation. 
The selection of donor grafts can be further improved by considering 
smoking history, in addition to well-known recipient and surgical pa-
rameters. These results warrant future investigation into the contri-
bution of donor risk factors for early thrombotic events of post OLT 
thrombosis.
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